Thomas E. Hutson

50.9k total citations · 9 hit papers
292 papers, 24.8k citations indexed

About

Thomas E. Hutson is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Thomas E. Hutson has authored 292 papers receiving a total of 24.8k indexed citations (citations by other indexed papers that have themselves been cited), including 258 papers in Pulmonary and Respiratory Medicine, 135 papers in Cancer Research and 129 papers in Molecular Biology. Recurrent topics in Thomas E. Hutson's work include Renal cell carcinoma treatment (223 papers), Cancer Genomics and Diagnostics (127 papers) and Renal and related cancers (113 papers). Thomas E. Hutson is often cited by papers focused on Renal cell carcinoma treatment (223 papers), Cancer Genomics and Diagnostics (127 papers) and Renal and related cancers (113 papers). Thomas E. Hutson collaborates with scholars based in United States, France and Italy. Thomas E. Hutson's co-authors include Robert J. Motzer, Stéphane Oudard, Robert A. Figlin, Ronald M. Bukowski, Sylvie Négrier, Cezary Szczylik, Bernard Escudier, M. Dror Michaelson, Piotr Tomczak and Sindy T. Kim and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Thomas E. Hutson

285 papers receiving 24.3k citations

Hit Papers

Sunitinib versus Interfer... 2007 2026 2013 2019 2007 2007 2008 2009 2010 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
    2007 4.5k citations Robert J. Motzer, Thomas E. Hutson et al. profile →
  2. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
    2007 3.8k citations Bernard Escudier, Tim Eisen et al. profile →
  3. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
  4. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
    2009 1.7k citations Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology profile →
  5. Phase 3 trial of everolimus for metastatic renal cell carcinoma
    2010 903 citations Robert J. Motzer, Bernard Escudier et al. profile →
  6. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
    2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
  7. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
    2015 688 citations Robert J. Motzer, Thomas E. Hutson et al. profile →
  8. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
    2013 542 citations Robert J. Motzer, Bernard Escudier et al. profile →
  9. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
    2011 457 citations Thomas E. Hutson, Cora N. Sternberg et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Thomas E. Hutson 17.8k 14.8k 9.2k 8.4k 2.7k 292 24.8k
Cezary Szczylik 15.9k 0.9× 14.1k 0.9× 8.5k 0.9× 8.1k 1.0× 1.7k 0.6× 322 23.8k
Sylvie Négrier 13.5k 0.8× 11.0k 0.7× 6.8k 0.7× 8.5k 1.0× 1.8k 0.7× 226 20.8k
M. Dror Michaelson 12.3k 0.7× 9.4k 0.6× 6.0k 0.6× 6.1k 0.7× 1.7k 0.6× 215 17.1k
Stéphane Oudard 27.5k 1.5× 16.5k 1.1× 12.0k 1.3× 13.8k 1.6× 3.4k 1.3× 618 38.8k
Ronald M. Bukowski 19.9k 1.1× 17.7k 1.2× 10.3k 1.1× 13.4k 1.6× 3.2k 1.2× 459 34.0k
Brian I. Rini 25.8k 1.4× 19.7k 1.3× 12.9k 1.4× 15.6k 1.9× 4.1k 1.5× 769 38.4k
Kim N. 20.4k 1.1× 6.7k 0.5× 8.0k 0.9× 8.6k 1.0× 1.6k 0.6× 369 26.1k
Christine Chevreau 10.2k 0.6× 6.3k 0.4× 3.8k 0.4× 6.2k 0.7× 2.7k 1.0× 310 15.6k
Karim Fizazi 25.3k 1.4× 6.5k 0.4× 8.0k 0.9× 14.8k 1.8× 5.0k 1.8× 835 36.7k
Fairooz F. Kabbinavar 8.8k 0.5× 7.8k 0.5× 4.1k 0.4× 12.9k 1.5× 2.5k 0.9× 175 21.8k

Countries citing papers authored by Thomas E. Hutson

Since Specialization
Citations

This map shows the geographic impact of Thomas E. Hutson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Hutson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Hutson more than expected).

Fields of papers citing papers by Thomas E. Hutson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Hutson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Hutson. The network helps show where Thomas E. Hutson may publish in the future.

Co-authorship network of co-authors of Thomas E. Hutson

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Hutson. A scholar is included among the top collaborators of Thomas E. Hutson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Hutson. Thomas E. Hutson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
McKay, Rana R., Pedro C. Barata, Moshe Chaim Ornstein, et al.. (2024). 5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605. The Oncologist. 29(Supplement_1). S13–S13. 1 indexed citations
3.
Christenson, Eric S., Daruka Mahadevan, Syed Mohammad Ali Kazmi, et al.. (2024). A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 2538–2538. 2 indexed citations
4.
Motzer, Robert J., Camillo Porta, Masatoshi Eto, et al.. (2024). Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.. Journal of Clinical Oncology. 42(16_suppl). 4504–4504. 7 indexed citations
5.
Beckermann, Kathryn E., Aviva G. Asnis-Alibozek, Michael B. Atkins, et al.. (2024). Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The Oncologist. 29(3). 254–262. 8 indexed citations
6.
McDermott, David H., Bernard Escudier, Thomas E. Hutson, et al.. (2024). Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study. The Oncologist. 30(2).
7.
Bergerot, Cristiane Decat, Paulo Gustavo Bergerot, Errol J. Philip, et al.. (2023). Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D.. Journal of Clinical Oncology. 41(16_suppl). 4540–4540.
8.
Rini, Brian I., Michael B. Atkins, Toni K. Choueiri, et al.. (2023). Plain Language Summary Looking at How Long Side Effects Last After Treatment with Axitinib is Stopped in People with Advanced Renal Cell Carcinoma. Future Oncology. 19(40). 2623–2629. 1 indexed citations
9.
Zengin, Zeynep Büşra, Sumanta K. Pal, David F. McDermott, et al.. (2022). Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. Clinical Genitourinary Cancer. 20(6). 553–557. 3 indexed citations
10.
11.
Meza, Luís, David F. McDermott, Bernard Escudier, et al.. (2022). Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3. The Oncologist. 28(3). e167–e170. 2 indexed citations
12.
Rini, Brian I., Michael B. Atkins, Toni K. Choueiri, et al.. (2021). Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 19(5). e306–e312. 13 indexed citations
13.
Szarek, Michael, Michael N. Needle, Brian I. Rini, et al.. (2021). Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. Clinical Genitourinary Cancer. 19(5). 468.e1–468.e5. 7 indexed citations
14.
Grünwald, Viktor, Thomas Powles, Toni K. Choueiri, et al.. (2019). Lenvatinib Plus Everolimus or Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Study Design and Rationale. Future Oncology. 15(9). 929–941. 38 indexed citations
15.
Choueiri, Toni K., André P. Fay, Robert Gagnon, et al.. (2013). The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. Clinical Cancer Research. 19(18). 5218–5226. 73 indexed citations
16.
Motzer, Robert J., Thomas E. Hutson, Piotr Tomczak, et al.. (2009). Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(22). 3584–3590. 1711 indexed citations breakdown →
17.
Escudier, Bernard, Cezary Szczylik, Thomas E. Hutson, et al.. (2009). Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(8). 1280–1289. 378 indexed citations
18.
Escudier, Bernard, Tim Eisen, Walter M. Stadler, et al.. (2009). Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Journal of Clinical Oncology. 27(20). 3312–3318. 864 indexed citations breakdown →
19.
Rini, Brian I., M. Dror Michaelson, Jonathan E. Rosenberg, et al.. (2008). Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 26(22). 3743–3748. 321 indexed citations
20.
Motzer, Robert J., Bernard Escudier, Stéphane Oudard, et al.. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet. 372(9637). 449–456. 2339 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cezary Szczylik Breakdown of academic impact, for papers by Sylvie Négrier Breakdown of academic impact, for papers by M. Dror Michaelson Breakdown of academic impact, for papers by Stéphane Oudard Breakdown of academic impact, for papers by Ronald M. Bukowski Breakdown of academic impact, for papers by Brian I. Rini Breakdown of academic impact, for papers by Kim N. Breakdown of academic impact, for papers by Christine Chevreau Breakdown of academic impact, for papers by Karim Fizazi Breakdown of academic impact, for papers by Fairooz F. Kabbinavar
Rankless by CCL
2026